FBR Capital Initiates Genocea Biosciences With Outperform

FBR Capital initiated coverage on

with a Outperform rating. The target price for Genocea Biosciences is set to $20. Genocea Biosciences shares have dropped 35.12 percent over the past 52 weeks, while the S&P 500 index has surged 11.75 percent in the same period. Genocea Biosciences' shares climbed 0.31 percent to close at $12.93 yesterday.